Market Newsdesk

CRANFORD, N.J., April 29, 2021 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok^® Phase 3 trial-related webinar. Mino-Lok^®, the Company’s lead product candidate, is an antibiotic lock therapy designed to salvage central venous catheters (CVCs) in patients with catheter related bloodstream infections (CRBSIs) or central line associated blood stream infections (CLABSIs). The webinar, led by Dr. Alan Lader, PhD, Vice President of Clinical Operations at Citius Pharmaceuticals was attended by investigators, clinical trial staff and referring physicians from trial sites participating in the Mino-Lok Phase 3 clinical trial.

“We are encouraged to see strong and growing interest within the clinical community in Mino-Lok as a potential treatment option for patients with CRBSI/CLABSI.  There are currently no FDA approved therapies to salvage infected CVCs,” stated Dr. Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Pharmaceuticals.

“We believe Mino-Lok has the potential to become the gold standard in CRBSI/CLABSI care, and the first and only FDA approved treatment option for salvaging catheters in patients with CRBSI/CLABSI,” added Myron Holubiak, President and Chief Executive Officer.

“Today, the standard of care for patients with CRBSI/CLABSI is to remove and replace a CVC.  By penetrating the biofilm, breaking down bacterial colonies and eradicating the bacteria, Mino-Lok‘s proprietary formulation has the potential to allow healthcare providers to salvage indwelling vascular catheters rather than replace them. This was our most well-attended webinar to date, which we believe is an indication of the importance of the work we are doing to address a critical unmet need in salvaging infected central lines,” concluded Dr. Lader.

The webinar agenda included a review of the formation of catheter biofilm, CLABSI treatment challenges with biofilm, pathogen responses to specific antimicrobials, and the benefits of Mino-Lok in addressing biofilm and CLABSI challenges.

About CRBSI/CLABSI

Central venous catheters (CVCs) are life-saving vascular access ports in patients requiring long-term intravenous therapy. CVCs are used to administer fluids, blood products, nutritional solutions, and medication, as well as for hemodynamic monitoring. While CVCs are important in treating many conditions, particularly in intensive care units, they pose a significant risk for device-related infections, and are a leading cause of morbidity and mortality. Of the approximately 7 million CVCs used annually in the US, about 500,000, or 7%, become infected, leading to serious, life-threatening infections called catheter-related bloodstream infections (CRBSIs).

It has been shown that antibiotics alone are unable to penetrate the biofilm caused by bacteria in the CVC, and there are currently no approved therapies for salvaging infected central venous catheters. The standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly, and 15% to 20% of the procedures are associated with significant morbidity.

About Mino-Lok®

Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). There are currently no approved therapies for salvaging infected CVCs. Mino-Lok is used in combination with an appropriate systemic antibiotic(s) to preserve central venous access and to avoid the complications and morbidities associated with catheter removal and reinsertion. Mino-Lok is currently enrolling subjects in its Phase 3 clinical trial. The U.S. Food and Drug Administration (FDA) granted Mino-Lok Qualified Infectious Disease (QDIP) and Fast Track designation.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company’s lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial.  Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.  For more information, please visit www.citiuspharma.com.

Safe Harbor

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates, including Mino-Lok®, and the risk of regulatory approval; the estimated markets for our product candidates and the acceptance thereof by any market; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Relations for Citius Pharmaceuticals:

Andrew Scott

Vice President, Special Projects
T: 908-967-6677 x105
E: [email protected]

Ilanit Allen

T: 908-967-6677 x113
E: [email protected]

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-reports-strong-clinical-community-engagement-during-mino-lok-phase-3-trial-related-webinar-301278389.html

SOURCE Citius Pharmaceuticals, Inc.

SEOUL, South Korea, April 29, 2021 /PRNewswire/ — On April 29, 2021, SK Telecom Co., Ltd. filed its Annual Report on Form 20-F for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission. The 2020 Annual Report on Form 20-F can be viewed on www.sktelecom.com, as well as from the website of the U.S. Securities and Exchange Commission at www.sec.gov.  Printed copies of SK Telecom’s complete audited financial statements (including footnotes) as of and for the year ended December 31, 2020 can be requested, free of charge, by written request to [email protected].

View original content:http://www.prnewswire.com/news-releases/sk-telecom-co-ltd-files-its-annual-report-on-form-20-f-301280355.html

SOURCE SK Telecom Co., Ltd

NEW YORK, April 29, 2021 /PRNewswire/ — Today, global media leader Oprah Winfrey announced Oprah’s Your Life in Focus: Spring Forward Stronger – Live Virtual Experience, a new, free, interactive, virtual experience presented and produced by WW International, Inc. (NASDAQ: WW) that will take place on Saturday, May 8 at 11am ET/8am PT. This 90-minute, live event is the second installment of a new quarterly series that kicked off this year and is inspired by Oprah and WW’s 2020 virtual event series and sold-out arena tour.

The special event is designed to celebrate and empower mothers, along with all parents, caregivers, and anyone who was forced to set their needs aside during this time, to spring forward stronger and lead their best, healthiest lives. The experience will feature a conversation with award-winning actress, talk show host, producer, business mogul and mother of two, Drew Barrymore.

During the May 8 live experience, Oprah will also be joined by therapist and popular host of the In the Light podcast, Dr. Anita Phillips, along with a special audience of inspiring mothers, parents and caregivers focused on reclaiming their health.

Watch a special message from Oprah HERE.

“As we look ahead to a new chapter, it’s important to reflect upon everything so many have sacrificed this past year,” said Oprah Winfrey. “This Mother’s Day weekend, let’s honor the collective resilience that we’ve shown in the face of adversity and set our sights on brighter days ahead.”

The “Oprah’s Your Life in Focus: Spring Forward Stronger” virtual event will kick off with an energizing pre-show followed by the main event with Drew Barrymore. Oprah and Drew will discuss what the past year has taught them about resilience – including Drew’s experience as a mother of two young children – and how it has helped inform their vision for the days ahead.

“As a mother and grandmother, I can say firsthand how much this topic means to me, particularly right now,” said Mindy Grossman, WW President and CEO. “We now know how important it is to care for the ones you love as well as the importance of putting yourself – and your health – first. We are so honored to have Oprah host another powerful event, which will inspire hope and help us reflect while coming together as a community to carve our path forward to wellness.”

In addition to inspiring and meaningful discussions, event participants will engage in an interactive workbook exercise to help them further prepare for the next steps in their health and wellness journeys.

“With the second installment of Oprah and WW’s quarterly series, we’re thrilled to continue to offer live, free, virtual experiences focusing on what matters most, as we look ahead to the future,” says Amy Weinblum, WW Chief Business Development Officer. “These intimate, interactive experiences allow people to reset, refocus and reconnect to themselves and each other and activate their healthiest, best lives.”

To join the free global experience, visit ww.com/oprah. Event registrants will receive a free digital workbook and a digital goodie bag inclusive of a special WW offer. The event will be hosted as a Zoom Video Webinar and live streamed on Oprah’s Facebook channel as well as WW’s Facebook and YouTube channels. It will remain available for on demand viewing across all platforms.

Media interested in additional information or with any press inquiries can fill out this form HERE.

About WW International, Inc.
WW (formerly Weight Watchers) is a human-centric technology company powered by the world’s leading commercial weight management program. As a global wellness company, we inspire millions of people to adopt healthy habits for real life. Through our comprehensive digital app, expert Coaches and engaging experiences, members follow our proven, sustainable, science-based program focused on food, activity, mindset and sleep. Leveraging nearly six decades of expertise in nutritional and behavioral change science, providing real human connection and building inspired communities, our purpose is to democratize and deliver holistic wellness for all. To learn more about the WW approach to healthy living, please visit ww.com. For more information about our global business, visit our corporate website at corporate.ww.com. 

For more information, contact:

Tracy Royal, WW
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ww-presents-oprahs-your-life-in-focus-spring-forward-stronger-virtual-experience-301280352.html

SOURCE WW International, Inc.

NEW YORK, April 29, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for AAPL, OSTK, GNRC, GILD, and CCL.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

• AAPL: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=AAPL&prnumber=042920213
• OSTK: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=OSTK&prnumber=042920213
• GNRC: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=GNRC&prnumber=042920213
• GILD: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=GILD&prnumber=042920213
• CCL: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=CCL&prnumber=042920213

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-apple-overstockcom-generac-holdings-gilead-sciences-or-carnival-corp-301280313.html

SOURCE InvestorsObserver

NEW YORK, April 29, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for HOFV, MRKR, LC, SNN, and CLOV.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

• HOFV: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=HOFV&prnumber=042920212
• MRKR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=MRKR&prnumber=042920212
• LC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=LC&prnumber=042920212
• SNN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=SNN&prnumber=042920212
• CLOV: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CLOV&prnumber=042920212

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-hall-of-fame-resort–entertainment-marker-therapeutics-lendingclub-smith–nephew-or-clover-health-investments-301280315.html

SOURCE InvestorsObserver

NEW YORK, April 29, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for QCOM, MRNA, FB, FLWS, and NCLH.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

• QCOM: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=QCOM&prnumber=042920214
• MRNA: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=MRNA&prnumber=042920214
• FB: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=FB&prnumber=042920214
• FLWS: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=FLWS&prnumber=042920214
• NCLH: https://www.investorsobserver.com/lp/pr-options-lp-2/?stocksymbol=NCLH&prnumber=042920214

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-qualcomm-moderna-facebook-1-800-flowerscom-or-norwegian-cruise-line-301280314.html

SOURCE InvestorsObserver

BOCA RATON, Fla., April 29, 2021 /PRNewswire/ — Curative Biotechnology, Inc.  (OTC: CUBT) a development stage biomedical company focused on novel therapies for rare diseases, announced today the Company’s trading symbol change from “CTYX” to “CUBT”. As previously announced, the Company had changed its corporate name to Curative Biotechnology, Inc. to better represent its mission to discover and develop therapeutics for patients who have few, if any, effective treatments for rare diseases.

Curative Biotechnology Inc. Chairman and President Paul Michaels said, “This name and symbol change are reflective of our total remaking of this company and our mission to create treatments or cures for unmet medical needs for patients around the world.”

Michaels added, “We are also very pleased to announce two additions to our Scientific and Clinical Advisory Board.  Both are important thought leaders in their respective fields and have joined our Scientific and Clinical Advisory Board to help guide our programs through pre-clinical and clinical development.”

Dr. Kapil Bharti

Kapil Bharti, Ph.D. from the National Eye Institute (NEI) at the National Institutes of Health (NIH) has joined our Scientific and Clinical Advisory Board.  Dr. Bharti is the lead inventor on the U.S. and Worldwide patent applications licensed exclusively to Curative Biotech to repurpose Metformin into an eye drop to treat degenerative eye diseases like macular degeneration, diabetic retinopathy, Stargardt’s disease, and others.  He is a world leader in his field, and we look forward to working closely with him as we prepare to move into clinical trials.

Dr. Bharti earned his Ph.D. from J.W. Goethe University, Frankfurt, Germany, graduating summa cum laude. He did his postdoc work at NIH, where he published numerous papers on pigment cell biology, transcription regulation and the developmental biology of the eye. Dr. Bharti has won a number of awards including being the first Earl Stadtman Tenure Track Investigator at NEI, NIH Directors award and NEI Directors Dr. Karl Kupfer Visionary award for his groundbreaking research on developing ocular cell-therapies.

Dr. Dimiter Dimitrov

Dimiter Dimitrov, Ph.D. earned his degrees at the University of Sofia, Sofia, Bulgaria, and subsequently joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990. He left for the University of Pittsburgh in 2017 to start their Center for Antibody Therapeutics, where he serves as director.  He was recently named one of 10 “Science Superheroes” by MediFind.

Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents.  Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma and has joined the company’s Scientific and Clinical Advisory Board to help guide the development of his invention into the clinic. 

Recent Addition to CEO’s Blog on Company Website

Richard Garr, CEO of Curative Biotech, recently added a post on the CEO’s Blog entitled, “Sometimes, starting big is the right decision”. As noted in the blog, the company has decided to pursue a reformulation of metformin which was licensed from the National Eye Institute for the treatment of wet Age-related Macular Degeneration (AMD). Curative expects to file an Investigational New Drug Application (IND) to begin human trials before the end of this year.

Curative Biotechnology – Novel Solutions for Unmet Medical Needs 

Future Curative Biotechnology Press Releases and Industry Updates

Interested investors and shareholders will receive press releases and industry updates by sending an e-mail to [email protected].

About Curative Biotechnology, Inc., 
http://curativebiotech.com

Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare diseases. Curative Biotech is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Curative Biotech, we envision a world where all patients have a therapeutic option.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/curative-biotechnology-inc-announces-finra-ticker-symbol-change-from-ctyx-to-cubt-301279767.html

SOURCE Curative Biotechnology

SALT LAKE CITY, April 29, 2021 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Lab (“CRL”) in a webinar titled “A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19” on Thursday, April 29 at 2:00 PM EDT.

The 360Dx webinar is expected to provide insights regarding future applications of PCR testing for COVID-19, how CRL is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection, and how new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests. Co-Diagnostics Senior Design Engineer Masen Christensen will discuss the results of ongoing monitoring and analyses of emerging COVID-19 mutations as they relate to the technology’s performance.

In November, CRL announced that it is selling its CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers. The CRL announcement states that the test uses CoPrimer™ probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity, and a simple saliva collection device that can be administered in virtually any setting, with results in typically 24 hours that are delivered via a secure online computer or mobile device platform.

Interested participants in the webinar can register here.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to rely on any forward-looking statements. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-and-partner-crl-to-discuss-saliva-testing-and-future-applications-of-pcr-in-360dx-webinar-301280326.html

SOURCE Co-Diagnostics

TSX Venture Exchange (TSX-V): GRG 
Frankfurt Stock Exchange (FSE): G6A
OTCQB Venture Market (OTCQB): GARWF

VANCOUVER, BC, April 29, 2021 /PRNewswire/ – Golden Arrow Resources Corporation (TSXV: GRG) (FSE: G6A) (OTCQB: GARWF), (“Golden Arrow” or the “Company”) is pleased to provide an update on exploration activities at its three most active projects, including the first results from the on-going trenching program at the Esperanza property of the Flecha de Oro gold project, Argentina. 

Phase I of the trenching program at Esperanza is focused on a nine square kilometre area where numerous gold-bearing quartz-veins have been identified at surface. Of particular note are results from a single vein, mapped over 540 metres of strike extent, that returned significant gold intervals in two separate trenches located approximately 160 metres apart, including:

• five metres averaging 2.98 g/t gold, including two metres averaging 6.21 g/t gold, in trench TE-10, and;
• one metre interval averaging 5.52 g/t gold in trench TE-6, located 160 metres east, in the same vein (see Figure 1: https://bit.ly/3udLQOw).

Golden Arrow VP Exploration and Development Brian McEwen commented, “We have seen from our previous surface sampling that there is widespread gold in the system at Esperanza, so we are encouraged to find some broader intervals in the near-surface that will help us vector into the heart of the system.”

Additional details from the trenching program, as well as other work in progress, are included below.  In addition to its exploration programs, Golden Arrow is continuing with its project acquisition efforts by constantly reviewing new opportunities to add to its exploration pipeline.  

Flecha de Oro Gold Project, Rio Negro Argentina
The Flecha de Oro Project includes the La Esperanza, Puzzle and Maquinchao exploration properties, consisting of 9,968, 1,952 and 2,000 hectares respectively, in central Rio Negro Province. The Project lies within the Somuncara Massif, where low and high sulphidation gold systems have been explored for since the first discovery of gold in the area in 1995. Examples of similar projects in the area include the Calcatreu low sulphidation gold-silver project located 165 kilometres to the southwest, hosting 746,000 oz of Indicated gold equivalent resources and a further 390,000 oz of Inferred AuEq resourcesⁱ.

At the La Esperanza property, Golden Arrow has identified similarities in size and geologic style to the Cerro Vanguardia district to the south in Santa Cruz province that has produced 4.5 million ounces of goldⁱⁱ, which is now being used as an exploration model.

[Readers are cautioned that results from other companies, including on properties proximal to those controlled by the Company, are not indicative of expected Golden Arrow results, as there has been insufficient exploration on these properties. These facts are simply used to aid in the exploration of these properties.]

Golden Arrow commenced the trenching program at Flecha de Oro in December 2020, with the initial work undertaken at the Puzzle property.   Results from the first 10 trenches at Puzzle identified gold in multiple samples over significant widths in several trenches (see Figure 2: https://bit.ly/2R7PpqU), but at grades below the threshold targeted by the Company.  As a result, the Esperanza property has been prioritized for on-going exploration. Esperanza hosts multiple vein corridors defined by outcropping quartz veins, boulders and quartz float.  The areas sampled by the trenches reported in this news release returned high-grade gold samples in earlier surface sampling programs (see Figure 1, and Company news releases dated March 2, 2020, December 3, 2019 and September 25, 2019).

Since the commencement of trenching at Esperanza on March 1^st, 2021, Golden Arrow has completed 20 trenches totaling 1,693 metres across surface quartz veins and sheeted veinlets that range from a few centimeters to two metres in width.  Assays have been received for 10 of these trenches.  An additional fifteen trenches are underway, and the Phase I program is expected to continue through most of May.   A summary of the results from the first ten trenches is presented in Table 1.

Table 1. Summary of Intervals >1g/t Au from Trenches 1 – 10, 

Esperanza target, Flecha de Oro Project.

Rosales Copper Project, Chile
Golden Arrow has awarded Quantec Geoscience Chile Ltda the contract for completing a new Transient Electromagnetic (TEM) surface geophysical survey at the Rosales Copper Project in May.  The goal of the program is to detect and delineate prospective electromagnetic conductor responses, consistent with near-surface copper stockwork mineralization, potentially related to Manto-type mineralized copper systems at depth. The program will be executed in two phases: 

• An initial test over approximately 300 hectares that includes known copper sulphide mineralization will be conducted and the results assessed to determine if the TEM technique successfully detects the mineralization.
• If successful, a second survey covering approximately 800 hectares will be completed.

Tierra Dorada Gold Project, Paraguay
The planned follow-up drill program at the Alvaro target has been delayed until permits are received that will allow deeper drilling.  While it is possible to continue with the shallow (<20m) drill hole program allowed by the existing permit, after further review of the initial shallow drilling results and the new targets identified by the IP geophysical survey (see News Release of January 9, 2021) it was concluded that there was greater benefit to waiting to be able to drill the deeper holes. Granting of permits has been delayed by outbreaks of COVID-19 within several government agencies and elsewhere in Paraguay. In the interim, the Golden Arrow exploration team has commenced a detailed soil sampling program over the new geophysical targets that have no surface outcrop to refine drill targets in those areas. In addition, mapping, trenching and surface sampling programs at the Alvaro target, and regionally throughout the project, are ongoing.  

For additional details on the Company’s main projects, please visit the website www.goldenarrowresources.com.

Methodology and QA/QC 

At the Flecha de Oro project, trenches were opened across the vein width and continued into the host rock on either side. Channel samples were cut along the trench walls with an electric saw and sampled in one-metre intervals.  Samples were shipped for preparation and analysis at ALS Laboratories, an internationally recognized assay service provider. Samples were prepared at their facility in Mendoza, Argentina and assayed for gold by Fire Assay/Atomic Absorption finish and analyzed for a multi-element package by ICP-OES following a four-acid digestion at their laboratory in Lima, Peru. The Company follows industry standard procedures for the work carried out on the Flecha de Oro Project, with a quality assurance/quality control (QA/QC) program. Blank, duplicate and standard samples were inserted in each batch of samples sent to the laboratory for analysis. Golden Arrow detected no significant QA/QC issues during review of the data.

Qualified Persons

The results of the Company’s exploration program have been reviewed, verified (including sampling, analytical and test data) and compiled by the Company’s geological staff under the supervision of Brian McEwen, P.Geol., VP Exploration and Development to the Company.  Mr. McEwen is a Qualified Person as defined in National Instrument 43-101, and has reviewed and approved the contents of the news release. 

About Golden Arrow:

Golden Arrow Resources Corporation is a mining exploration company with a successful track record of creating value by making precious and base metal discoveries and advancing them into exceptional deposits. The Company is well leveraged to the price of gold, having monetized its Chinchillas silver discovery into a significant holding in precious metals producer SSR Mining Inc.

Golden Arrow is actively exploring a portfolio that includes a new epithermal gold project in Argentina, a district–scale frontier gold opportunity in Paraguay, a base-metal project in the heart of a leading mining district in Chile and more than 180,000 hectares of properties in Argentina.

The Company is a member of the Grosso Group, a resource management group that has pioneered exploration in Argentina since 1993.

ON BEHALF OF THE BOARD

“Joseph Grosso”

_______________________________
Mr. Joseph Grosso,
Executive Chairman, President and CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements.  Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. All statements, other than statements of historical fact, that address activities, events or developments the Company believes, expects or anticipates will or may occur in the future, including, without limitation, statements about the Company’s plans for its mineral properties; the Company’s business strategy, plans and outlooks; the future financial or operating performance of the Company; and future exploration and operating plans are forward-looking statements. 

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things: the impact of COVID-19; risks and uncertainties related to the ability to obtain, amend, or maintain licenses, permits, or surface rights; risks associated with technical difficulties in connection with mining activities; and the possibility that future exploration, development or mining results will not be consistent with the Company’s expectations. 
Actual results may differ materially from those currently anticipated in such statements. Readers are encouraged to refer to the Company’s public disclosure documents for a more detailed discussion of factors that may impact expected future results. The Company undertakes no obligation to publicly update or revise any forward-looking statements, unless required pursuant to applicable laws. 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/golden-arrow-provides-exploration-update-and-reports-trench-results-from-flecha-de-oro-project-argentina-301280332.html

SOURCE Golden Arrow Resources Corporation